This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.
This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

Ashwin Urkude Article rating: 3.7

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

Maximize Your Investment Potential with This Small Cap Fund
Maximize Your Investment Potential with This Small Cap Fund

Maximize Your Investment Potential with This Small Cap Fund

In this article, you will discover the top five mutual funds that delivered the highest returns in the past year, followed by an in-depth analysis of one of these funds.

Ashwin Urkude Article rating: 4.3

In this article, you will discover the top five mutual funds that delivered the highest returns in the past year, followed by an in-depth analysis of one of these funds.

Clocked Upper circuit: This real estate stock soars over 5 per cent after record-breaking sales
Clocked Upper circuit: This real estate stock soars over 5 per cent after record-breaking sales

Clocked Upper circuit: This real estate stock soars over 5 per cent after record-breaking sales

The company's record-breaking sales performance in Q4FY24 and FY24, which likely boosted investor confidence, has led to a significant increase in the stock price.

Ashwin Urkude Article rating: 5.0

The company's record-breaking sales performance in Q4FY24 and FY24, which likely boosted investor confidence, has led to a significant increase in the stock price.

Supercharge your portfolio: Must-Know thematic funds for 2024
Supercharge your portfolio: Must-Know thematic funds for 2024

Supercharge your portfolio: Must-Know thematic funds for 2024

These thematic funds have been market superstars, boasting returns exceeding 90 per cent in just one year!

Ashwin Urkude Article rating: 3.0

These thematic funds have been market superstars, boasting returns exceeding 90 per cent in just one year!

RSS
1345678910Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR